[Featured Stock] Russian COVID-19 Vaccine-Related Stock 'HumanN'... Hits Upper Limit on News of Development Team Visiting Korea

[Asia Economy Reporter Park Jihwan] HumanN's stock price surged to the upper limit on the 26th following the news of the visit of the research team that developed the COVID-19 vaccine 'Covivac'.

As of 2:50 PM that day, HumanN was trading at 8,850 KRW, up 29.96% (2,040 KRW) from the previous day.

The strong performance of HumanN's stock is interpreted as a result of the news of the visit to Korea by key researchers, including Aidar Ishmukhametov, the head of the Chumakov Institute, which developed Covivac.

According to related industries, the research team from the Chumakov Institute is preparing to visit Korea next month. Officials planning the visit have currently applied for quarantine exemption approval through the Corporate Immigration Support Center.

Covivac is a COVID-19 vaccine that received approval for use from the Russian Ministry of Health in February. The Chumakov Institute has currently applied to the World Health Organization (WHO) for the official prequalification (PQ) of the Covivac vaccine.

In Korea, MP Corporation is in charge of overseeing the Covivac project and signed a memorandum of understanding (MOU) in February for the domestic contract manufacturing of the Covivac vaccine and exclusive distribution rights in ASEAN countries. HumanN is classified as a Covivac-related stock, having invested approximately 7 billion KRW each in Webiotech and MP Corporation.